
HCWB Valuation
HCW Biologics Inc
- Overview
- Forecast
- Valuation
- Earnings
HCWB Relative Valuation
HCWB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCWB is overvalued; if below, it's undervalued.
Historical Valuation
HCW Biologics Inc (HCWB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.10 is considered Undervalued compared with the five-year average of -3.02. The fair price of HCW Biologics Inc (HCWB) is between 14.25 to 118.10 according to relative valuation methord. Compared to the current price of 4.13 USD , HCW Biologics Inc is Undervalued By 71.02%.
Relative Value
Fair Zone
14.25-118.10
Current Price:4.13
71.02%
Undervalued
-0.77
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
HCW Biologics Inc. (HCWB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.92. The thresholds are as follows: Strongly Undervalued below -3.16, Undervalued between -3.16 and -2.04, Fairly Valued between 0.20 and -2.04, Overvalued between 0.20 and 1.32, and Strongly Overvalued above 1.32. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.07
EV/EBIT
HCW Biologics Inc. (HCWB) has a current EV/EBIT of -2.07. The 5-year average EV/EBIT is -3.22. The thresholds are as follows: Strongly Undervalued below -13.42, Undervalued between -13.42 and -8.32, Fairly Valued between 1.88 and -8.32, Overvalued between 1.88 and 6.98, and Strongly Overvalued above 6.98. The current Forward EV/EBIT of -2.07 falls within the Historic Trend Line -Fairly Valued range.
1.10
PS
HCW Biologics Inc. (HCWB) has a current PS of 1.10. The 5-year average PS is 276.72. The thresholds are as follows: Strongly Undervalued below -1535.50, Undervalued between -1535.50 and -629.39, Fairly Valued between 1182.83 and -629.39, Overvalued between 1182.83 and 2088.94, and Strongly Overvalued above 2088.94. The current Forward PS of 1.10 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
HCW Biologics Inc. (HCWB) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.24. The thresholds are as follows: Strongly Undervalued below -7.91, Undervalued between -7.91 and -4.58, Fairly Valued between 2.09 and -4.58, Overvalued between 2.09 and 5.42, and Strongly Overvalued above 5.42. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
HCW Biologics Inc. (HCWB) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.43. The thresholds are as follows: Strongly Undervalued below -1.98, Undervalued between -1.98 and -1.20, Fairly Valued between 0.34 and -1.20, Overvalued between 0.34 and 1.11, and Strongly Overvalued above 1.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
HCW Biologics Inc (HCWB) has a current Price-to-Book (P/B) ratio of -0.56. Compared to its 3-year average P/B ratio of -0.63 , the current P/B ratio is approximately -11.93% higher. Relative to its 5-year average P/B ratio of -0.16, the current P/B ratio is about 254.38% higher. HCW Biologics Inc (HCWB) has a Forward Free Cash Flow (FCF) yield of approximately -184.72%. Compared to its 3-year average FCF yield of -68.08%, the current FCF yield is approximately 171.33% lower. Relative to its 5-year average FCF yield of -53.43% , the current FCF yield is about 245.72% lower.
-0.56
P/B
Median3y
-0.63
Median5y
-0.16
-184.72
FCF Yield
Median3y
-68.08
Median5y
-53.43
Competitors Valuation Multiple
The average P/S ratio for HCWB's competitors is 15.90, providing a benchmark for relative valuation. HCW Biologics Inc Corp (HCWB) exhibits a P/S ratio of 1.10, which is -93.06% above the industry average. Given its robust revenue growth of -99.55%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HCWB decreased by 82.82% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -662.82 to -43.37K.
The secondary factor is the Revenue Growth, contributed -99.55%to the performance.
Overall, the performance of HCWB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch

JZ
Jianzhi Education Technology Group Co Ltd
1.760
USD
+3.53%

JCTC
Jewett-Cameron Trading Company Ltd
3.410
USD
+0.29%

XIN
Xinyuan Real Estate Co Ltd
2.247
USD
+0.31%

STRM
Streamline Health Solutions Inc
5.300
USD
-0.09%

MNTS
Momentus Inc
1.170
USD
-2.50%

SUGP
SU Group Holdings Ltd
0.810
USD
-10.00%

SKK
SKK Holdings Ltd
0.600
USD
-1.15%

UONE
Urban One Inc
1.840
USD
+1.66%

KNW
Know Labs Inc
2.540
USD
+4.10%

RMCO
Royalty Management Holding Corp
1.340
USD
+0.75%
FAQ

Is HCW Biologics Inc (HCWB) currently overvalued or undervalued?
HCW Biologics Inc (HCWB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.10 is considered Undervalued compared with the five-year average of -3.02. The fair price of HCW Biologics Inc (HCWB) is between 14.25 to 118.10 according to relative valuation methord. Compared to the current price of 4.13 USD , HCW Biologics Inc is Undervalued By 71.02% .

What is HCW Biologics Inc (HCWB) fair value?

How does HCWB's valuation metrics compare to the industry average?

What is the current P/B ratio for HCW Biologics Inc (HCWB) as of Jul 29 2025?

What is the current FCF Yield for HCW Biologics Inc (HCWB) as of Jul 29 2025?

What is the current Forward P/E ratio for HCW Biologics Inc (HCWB) as of Jul 29 2025?
